In an action relating to amlodipine besylate (Pfizer’s NORVASC), Apotex is seeking relief in the Quebec Superior Court pursuant to the Ontario Statute of Monopolies, U.K. Statute of Monopolies, the Trade-marks Act, and unjust enrichment. Pfizer brought a motion to dismiss Apotex’s claim. On April 25, 2018, the Quebec Superior Court dismissed an application by Pfizer (part of the motion to dismiss) to dismiss the action, finding that the Quebec Superior Court has jurisdiction to adjudicate Apotex’s claim under the Ontario Statute of Monopolies: Apotex Inc c Pfizer Limited, 2018 QCCS 1765. The balance of Pfizer’s motion to dismiss has been deferred to the trial in the liability phase of the proceeding.
Related Publications & Articles
-
Alexion awarded injunction against Amgen in SOLIRIS patent action; Court considers anticipation by incorporation by reference
The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, using, and selling its proposed biosimilar eculizumab product, BEKEMV, in Can...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More